| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Itraconazole-d9 is the deuterated form of itraconazole, which itself is a potent inhibitor of the Hedgehog (Hh) signaling pathway with an IC₅₀ of approximately 800 nM. Itraconazole also effectively inhibits lanosterol 14α-demethylase (a cytochrome P450 enzyme), which is crucial for ergosterol synthesis in fungal cell membranes. The deuterated version retains the same target specificity as the parent compound and is utilized as a tracer to study the pharmacological profile of itraconazole, particularly in the context of its antifungal activity and its role as a Hedgehog pathway antagonist.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
The in vitro activity of Itraconazole-d9 is presumed to mirror that of its non-deuterated parent compound, Itraconazole. Itraconazole exhibits potent antifungal activity by inhibiting ergosterol synthesis, disrupting fungal cell membrane integrity. Additionally, it functions as a Hedgehog signaling pathway antagonist with an IC₅₀ of ~800 nM, which has been investigated for its anti-cancer properties. The deuterated form is used in in vitro assays primarily as an internal standard to accurately measure the concentration of the parent drug in cell-based experiments, rather than as an active compound itself. |
| ln Vivo |
The in vivo activity of Itraconazole-d9 corresponds to the pharmacological effects of Itraconazole. As an orally active antifungal agent, Itraconazole is widely used to treat various systemic fungal infections. Its activity as a Hedgehog pathway antagonist has also been explored in vivo for therapeutic applications. In research settings, the deuterated form serves as an ideal internal standard for pharmacokinetic studies, enabling precise tracking of drug absorption, distribution, metabolism, and excretion (ADME) without interfering with the biological activity of the parent drug.
|
| Enzyme Assay |
The primary experimental use of Itraconazole-d9 is as an internal standard in analytical chemistry rather than in traditional enzyme/receptor binding assays. In a typical LC-MS/MS workflow, a known amount of Itraconazole-d9 is spiked into a biological sample (e.g., plasma or tissue homogenate). The sample is then processed through protein precipitation or solid-phase extraction. The analyte (Itraconazole) and the internal standard (Itraconazole-d9) are separated via liquid chromatography and detected by mass spectrometry. The distinct mass-to-charge ratio of the deuterated compound allows for accurate quantification of the non-labeled drug by correcting for matrix effects and sample preparation variability.
|
| Cell Assay |
In cellular assays, Itraconazole-d9 is not typically used to elicit a biological response but rather to quantify the uptake and metabolism of itraconazole. Cells are treated with Itraconazole, and the internal standard is added to the cell lysates or culture media before analysis. The samples are then processed and analyzed by LC-MS/MS to determine the intracellular concentration of Itraconazole. This approach allows researchers to study drug transport, accumulation, and metabolism in various cell lines, providing critical data for understanding the compound's cellular pharmacokinetics.
|
| Animal Protocol |
In animal studies, Itraconazole-d9 is co-administered or used as a tracking standard for the parent compound. Following administration of Itraconazole to animal models (typically rodents), blood samples are collected at various time points. Itraconazole-d9 is added to these samples as an internal standard before LC-MS/MS analysis. This methodology enables the precise determination of pharmacokinetic parameters such as half-life, clearance, and bioavailability, which are essential for evaluating the in vivo performance of the drug.
|
| ADME/Pharmacokinetics |
As a stable isotope-labeled compound, Itraconazole-d9 is metabolically stable, allowing it to function effectively as an internal standard without significant degradation during sample processing. It is soluble in DMSO and other organic solvents, and its deuterium labeling provides a distinct mass shift for analytical detection. Pharmacokinetic studies utilizing this internal standard can accurately determine the ADME profile of Itraconazole, including its oral bioavailability, tissue distribution, and metabolic pathways. The compound should be stored at -20°C in powder form for up to 3 years and as a solution at -20°C for up to 6 months.
|
| Toxicity/Toxicokinetics |
Itraconazole-d9 is intended for research use only and is not for therapeutic or diagnostic use in humans. Standard laboratory safety practices should be followed when handling this compound. As a stable isotope, it is non-radioactive and poses minimal radiological risk, but its toxicological profile is expected to be similar to that of the parent drug, Itraconazole, which is generally well-tolerated at therapeutic doses but may have hepatotoxic effects at high concentrations.
|
| References |
|
| Additional Infomation |
Itraconazole-d9 is a high-purity (typically >98%) stable isotope-labeled compound used exclusively as an analytical standard. It is known by the synonyms R51211-d9. The incorporation of nine deuterium atoms into the Itraconazole molecule makes it a gold-standard internal standard for bioanalysis, ensuring high accuracy and precision in the quantification of Itraconazole in complex biological matrices. It is an essential tool in drug development and clinical research for studying the pharmacokinetics and metabolism of this important antifungal agent.
|
| Molecular Formula |
C35H29D9CL2N8O4
|
|---|---|
| Molecular Weight |
714.69
|
| Exact Mass |
713.296
|
| CAS # |
1309272-50-1
|
| Related CAS # |
Itraconazole;84625-61-6
|
| PubChem CID |
118988633
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
49
|
| Complexity |
1120
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
[2H]C([2H])([2H])C([2H])([2H])C([2H])(C([2H])([2H])[2H])N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3992 mL | 6.9960 mL | 13.9921 mL | |
| 5 mM | 0.2798 mL | 1.3992 mL | 2.7984 mL | |
| 10 mM | 0.1399 mL | 0.6996 mL | 1.3992 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
